In 2018, Pharmstandard-Leksredstva, a drug manufacturer, will launch the production of Russian-made medicines for asthma patients, announced the press office of the Kursk region administration. The project worth 1.9 billion rubles was presented at the Russian Investment Forum in Sochi.
“This year, Pharmstandard-Leksredstva will complete its 1.9 billion ruble project to establish the manufacturing of import substituting drugs against asthma. This will allow the Kursk-based company to become the main Russian manufacturer of drugs for the treatment of obstructive respiratory diseases,” said the regional administration.
Pharmstandard-Leksredstva, a Kursk-based company, is part of Pharmstandard Group, which owns eight pharmaceutical plants.